Commercial analytics for biotech and pharma

Find your next indication.

We size the patients, build the forecast and map the patient journey, so you can see where an asset goes next and what it is worth when it gets there.

01Population

Every forecast starts with the right patients.

We turn incidence and prevalence into the population that matters for your decision. Diagnosis, stage, biomarker, eligibility and line of therapy, each step sourced and open to challenge.

02Forecast

Three cases. Zero black boxes.

Patient-based demand and revenue forecasts with every assumption on the table. Base, upside and downside, and the conditions that would make each one true.

03Journey

See where patients stall.

We reconstruct real patient journeys from event data, find the delays and missed handoffs, and turn them into exception reports your operations team acts on.

04Decision

Then choose with evidence.

Indications compared on the same patients, the same competitors and the same assumptions. A clear brief on where to go next, and what would change the answer.

Team experience

Trained inside big pharma.
Built for biotech.

Before NextIndication, our team worked in oncology commercial insights and patient-services analytics at top-10 global pharma companies.

12

oncology projects with country-level epidemiology and patient-flow models

10+

oncology assets with patient-based forecasts

9+

priority projects run on one standardized scenario approach

99.8%

match to official sources on a one-billion-record data pipeline

Team experience before NextIndication. Project counts overlap and are not added together.

Oncology commercial insights

Epidemiology, forecasting and asset assessment across solid tumours and haematological cancers, from literature review to the executive presentation.

Patient-services analytics

Product ownership of patient process-mining tools and an automated exception report that operations teams use every cycle.

Research rigour

Doctoral research in computational genomics with peer-reviewed publications, plus quantitative research on billion-record datasets.

What we do

One team for the whole
chain of evidence.

Core practice

Commercial strategy and forecasting

Epidemiology, patient flows and patient-based forecasts with scenarios and sensitivity. The centre of every asset decision.

  • Epidemiology models
  • Patient-based forecasts
  • Scenarios and sensitivity
  • Analog benchmarking

Our namesake

Asset and indication assessment

Compare indications, assets and deals on one consistent set of patients, competitors and assumptions.

Competitive intelligence

Pipelines mapped by indication, mechanism, stage and setting, with updates focused on what changes your decision.

Core practice

Patient and process analytics

Process mining for patient-support programs. See how cases really move, where they wait and what happens after you act.

  • Journey reconstruction
  • Exception reporting
  • Value measurement
  • Analytics product ownership

Valuation and deal modelling

From forecast to risk-adjusted value, milestones and royalties, so the science and the numbers stay linked.

Automation and data builds

Reporting pipelines, monitoring and scenario tools that replace manual preparation and keep running after we leave.

Biology-literate

Doctoral training in computational genomics means we read the evidence behind the asset, not only the market around it.

Live model

Move an assumption.
Watch the forecast move.

A simplified version of how we build: patients first, every driver visible. Try it.

Population
Uptake and price
Addressable patients per year0
On therapy at peak0
Peak annual revenue$0
12-year revenue$0
Incident0
Biomarker-positive0
Drug-treated0
On therapy at peak0

Illustrative model with synthetic assumptions. It is not a forecast for any real product.

Patient journeys

Find the stall. Flag the case.
Follow it through.

Most reports show how many patients sit in each status. We show how they move, where they wait and which ones need a person to look today.

0Cases in journey
0Waiting past threshold
0Flagged for review
0Resolved after review

Simulated cases for illustration.

Reconstruct

Rebuild every journey from recorded events and timestamps. Common routes, detours, repeats and the ones that never finish.

Flag

Explicit review rules with time thresholds and exclusions, delivered as a list your team can act on inside its existing workflow.

Measure

Track which flagged cases were reviewed and what happened next, with clear denominators and honest observation windows.

Where to start

Start with one decision.

How big is this, really?

Asset opportunity assessment

  • Patient-flow model
  • Editable patient-based forecast
  • Scenario comparison and decision presentation

Can we trust this model?

Forecast health check

  • Independent review of logic, overrides and sources
  • Issue list ranked by impact
  • Corrected workbook with documentation

Where are patients getting stuck?

Patient-journey diagnostic

  • Event-data assessment
  • Journey map and delay analysis
  • Prioritized improvement questions

What just changed?

Competitive landscape monitor

  • Structured asset database
  • Recurring change report
  • Implications for your asset or indication

What is it worth?

Forecast to valuation

  • Forecast linked to a product-level financial view
  • Risk-adjusted value as a range
  • Deal-term scenarios

How we work

Transparent by default.

  1. 1

    Frame

    We start from the decision you need to make, not from the data you happen to have.

  2. 2

    Build

    Patients first. Every assumption is explicit, sourced and editable.

  3. 3

    Stress-test

    Scenarios and sensitivities show what drives the answer and what would change it.

  4. 4

    Hand over

    You keep the model, the sources and the documentation. No black boxes, no lock-in.

Get in touch

What's your next indication?

Tell us the decision in front of you. We will tell you what it takes to answer it.